Literature DB >> 20598829

Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: National surveys of physicians.

Cynthia L Arfken1, Chris-Ellyn Johanson, Salvatore di Menza, Charles Roberts Schuster.   

Abstract

Office-based treatment of opioid dependence with buprenorphine has the potential to expand treatment capacity in the United States. However, nationally, little is known about the number, characteristics, and experiences of physicians certified to prescribe buprenorphine. Moreover, little is known about the impact of easing federal regulations on the number of patients a physician is allowed to treat concurrently. To address these questions, surveys of national samples of physicians certified to prescribe buprenorphine (2004-2008) were analyzed (N = 6,892). There has been a continual increase in the number of physicians certified to prescribe buprenorphine, increase in the mean number of patients treated by physicians, and decrease in patients turned away, coinciding temporally with easing of federal regulations. In addition, most physicians prescribed buprenorphine outside of traditional treatment settings. The U.S. experiment in expanding Schedule III-V medications for opioid dependence to physicians outside of formal substance abuse treatment facilities appears to have resulted in expanded capacity. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20598829     DOI: 10.1016/j.jsat.2010.05.004

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  62 in total

1.  Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial.

Authors:  Roger D Weiss; Jennifer Sharpe Potter; David A Fiellin; Marilyn Byrne; Hilary S Connery; William Dickinson; John Gardin; Margaret L Griffin; Marc N Gourevitch; Deborah L Haller; Albert L Hasson; Zhen Huang; Petra Jacobs; Andrzej S Kosinski; Robert Lindblad; Elinore F McCance-Katz; Scott E Provost; Jeffrey Selzer; Eugene C Somoza; Susan C Sonne; Walter Ling
Journal:  Arch Gen Psychiatry       Date:  2011-11-07

2.  Using a Learning Collaborative Strategy With Office-based Practices to Increase Access and Improve Quality of Care for Patients With Opioid Use Disorders.

Authors:  Benjamin R Nordstrom; Elizabeth C Saunders; Bethany McLeman; Andrea Meier; Haiyi Xie; Chantal Lambert-Harris; Beth Tanzman; John Brooklyn; Gregory King; Nels Kloster; Clifton Frederick Lord; William Roberts; Mark P McGovern
Journal:  J Addict Med       Date:  2016 Mar-Apr       Impact factor: 3.702

3.  Practice Guidance for Buprenorphine for the Treatment of Opioid Use Disorders: Results of an Expert Panel Process.

Authors:  Carrie M Farmer; Dawn Lindsay; Jessica Williams; Amanda Ayers; James Schuster; Alyssa Cilia; Michael T Flaherty; Todd Mandell; Adam J Gordon; Bradley D Stein
Journal:  Subst Abus       Date:  2015-04-06       Impact factor: 3.716

4.  County-level access to opioid use disorder medications in medicare Part D (2010-2015).

Authors:  Amanda J Abraham; Grace Bagwell Adams; Ashley C Bradford; William D Bradford
Journal:  Health Serv Res       Date:  2019-01-21       Impact factor: 3.402

5.  National and State Treatment Need and Capacity for Opioid Agonist Medication-Assisted Treatment.

Authors:  Christopher M Jones; Melinda Campopiano; Grant Baldwin; Elinore McCance-Katz
Journal:  Am J Public Health       Date:  2015-06-11       Impact factor: 9.308

6.  A Mixed-Method Analysis of Reports on 100 Cases of Improper Prescribing of Controlled Substances.

Authors:  James M DuBois; John T Chibnall; Emily E Anderson; Michelle Eggers; Kari Baldwin; Meghan Vasher
Journal:  J Drug Issues       Date:  2016-08-09

7.  I heard about it from a friend: assessing interest in buprenorphine treatment.

Authors:  Aaron D Fox; Pooja A Shah; Nancy L Sohler; Carolina M Lopez; Joanna L Starrels; Chinazo O Cunningham
Journal:  Subst Abus       Date:  2014       Impact factor: 3.716

8.  Buprenorphine Prescribing Availability in a Sample of Ohio Specialty Treatment Organizations.

Authors:  Todd Molfenter; Carol Sherbeck; Mark Zehner; Sandy Starr
Journal:  J Addict Behav Ther Rehabil       Date:  2015

9.  National Trends in Adolescent Substance Use Disorders and Treatment Availability: 2003-2010.

Authors:  Amy A Mericle; Amelia M Arria; Kathy Meyers; John Cacciola; Ken C Winters; Kim Kirby
Journal:  J Child Adolesc Subst Abuse       Date:  2015

10.  Establishing the feasibility of measuring performance in use of addiction pharmacotherapy.

Authors:  Cindy Parks Thomas; Deborah W Garnick; Constance M Horgan; Kay Miller; Alex H S Harris; Melissa M Rosen
Journal:  J Subst Abuse Treat       Date:  2013-03-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.